Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19.

Data de publicació: Data Ahead of Print:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Rodilla E
  • Saura A
  • Jiménez I
  • Mendizábal A
  • Pineda-Cantero A
  • Lorenzo-Hernández E
  • Fidalgo-Montero MDP
  • López-Cuervo JF
  • Rabadán-Pejenaute E
  • Abella-Vázquez L
  • Giner-Galvañ V
  • Solís-Marquínez MN
  • Boixeda R
  • Peña-Fernández A
  • Carrasco-Sánchez FJ
  • González-Moraleja J
  • Torres-Peña JD
  • Guisado-Espartero ME
  • Escobar-Sevilla J
  • Guzmán-García M
  • Martín-Escalante MD
  • Martínez-González ÁL
  • Casas-Rojo JM
  • Gómez-Huelgas R

Grups d'Investigació

Abstract

It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 ± 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.

Dades de la publicació

ISSN/ISSNe:
2077-0383, 2077-0383

Journal of clinical medicine  MDPI AG

Tipus:
Article
Pàgines:
-
PubMed:
32998337

Cites Rebudes en Web of Science: 56

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • COVID-19, all-cause mortality, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), hypertension

Campos d'Estudi

Compartir la publicació